Global Bioinformatics Market Projected to Reach USD 9.1 Billion in 2018
|
By LabMedica International staff writers Posted on 10 Dec 2012 |
|
Projected to record double-digit growth, the global informatics market will have the highest revenue contribution from the platforms segment.
The global bioinformatics market, estimated at USD 2.3 billion in 2012, is forecasted to reach a market size of USD 9.1 billion in 2018, at a compounded annual growth rate (CAGR) of 25.4% from 2012-2018, according to Transparency Market Research (Albany, NY, USA; www.transparencymarketresearch.com). The market growth is motivated by a rise in applications across a range of industries. The major contribution to the market demand is from fields such as pharmaceutical research and development, agriculture biotechnology, medical and clinical diagnostics, and other life-sciences related industries.
The services market currently holds a comparatively smaller market share; however, it is expected to increase considerably over the forecast period. The bioinformatics platform segment is the fastest growing market and is expected to contribute 54% of the total market growth during the same period.
Research outsourcing by pharmaceutical giants in the fields comprising bioinformatics content is a significant driver of the global bioinformatics market. These companies, in efforts to decrease time and costs on R&D activities involved in the development of new medicines and new applications for existing drugs, are looking for outsourcing services for bioinformatics knowledge and management tools, platforms, and services.
North America holds the largest share among the regional markets; it, however, is forecasted to be superseded by Europe as the leading market shareholder in 2018, because of rapid growth seen by major European markets such as the United Kingdom and Germany. Europe is predicted to be the fastest growing region, with growth chiefly driven by mounting government support for R&D activities in the region. The bioinformatics services market in Europe and North America is well established and organized, while it is still in an early growth phase in emerging markets of Asia Pacific region.
Related Links:
Transparency Market Research
The global bioinformatics market, estimated at USD 2.3 billion in 2012, is forecasted to reach a market size of USD 9.1 billion in 2018, at a compounded annual growth rate (CAGR) of 25.4% from 2012-2018, according to Transparency Market Research (Albany, NY, USA; www.transparencymarketresearch.com). The market growth is motivated by a rise in applications across a range of industries. The major contribution to the market demand is from fields such as pharmaceutical research and development, agriculture biotechnology, medical and clinical diagnostics, and other life-sciences related industries.
The services market currently holds a comparatively smaller market share; however, it is expected to increase considerably over the forecast period. The bioinformatics platform segment is the fastest growing market and is expected to contribute 54% of the total market growth during the same period.
Research outsourcing by pharmaceutical giants in the fields comprising bioinformatics content is a significant driver of the global bioinformatics market. These companies, in efforts to decrease time and costs on R&D activities involved in the development of new medicines and new applications for existing drugs, are looking for outsourcing services for bioinformatics knowledge and management tools, platforms, and services.
North America holds the largest share among the regional markets; it, however, is forecasted to be superseded by Europe as the leading market shareholder in 2018, because of rapid growth seen by major European markets such as the United Kingdom and Germany. Europe is predicted to be the fastest growing region, with growth chiefly driven by mounting government support for R&D activities in the region. The bioinformatics services market in Europe and North America is well established and organized, while it is still in an early growth phase in emerging markets of Asia Pacific region.
Related Links:
Transparency Market Research
Gold Member
Hematology Analyzer
Medonic M32B
Gold Member
Collection and Transport System
PurSafe Plus®
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Latest BioResearch News
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
Channels
Clinical Chemistry
view channel
New Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read more
Molecular Diagnostics
view channel
Ultra-Sensitive DNA Test Identifies Relapse Risk in Aggressive Leukemia
Acute myeloid leukemia (AML) is a rare but aggressive blood cancer in which relapse after allogeneic stem cell transplant remains a major clinical challenge, particularly for patients with NPM1-mutated disease.... Read more
Blood Test Could Help Detect Gallbladder Cancer Earlier
Gallbladder cancer is one of the deadliest gastrointestinal cancers because it is often diagnosed at an advanced stage when treatment options are limited. Early symptoms are minimal, and current screening... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Hidden Gut Viruses Linked to Colorectal Cancer Risk
Colorectal cancer (CRC) remains a leading cause of cancer mortality in many Western countries, and existing risk-stratification approaches leave substantial room for improvement. Although age, diet, and... Read more
Three-Test Panel Launched for Detection of Liver Fluke Infections
Parasitic liver fluke infections remain endemic in parts of Asia, where transmission commonly occurs through consumption of raw freshwater fish or aquatic plants. Chronic infection is a well-established... Read more
Pathology
view channel
Molecular Imaging to Reduce Need for Melanoma Biopsies
Melanoma is the deadliest form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Because early melanomas can closely resemble benign moles, clinicians often rely on visual... Read more
Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
Urine testing is a critical, non-invasive diagnostic tool used to detect conditions such as pregnancy, urinary tract infections, metabolic disorders, cancer, and kidney disease. However, contaminated or... Read more
Technology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more